Proposed Decision Memo for Screening for Cervical Cancer with Human Papillomavirus (HPV) Testing

CMS proposes that the evidence is sufficient to add Human Papillomavirus (HPV) testing once every five years as an additional preventive service benefit under the Medicare program for asymptomatic beneficiaries aged 30 to 65 years in conjunction with the Pap smear test. CMS will cover screening for cervical cancer with the appropriate FDA approved/cleared laboratory tests, used consistent with FDA approved labeling and in compliance with CLIA regulations. CMS is seeking comments on their proposed decision and will respond to public comments in a final decision memorandum.